ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (AIM:AGL) announced its interim results for the six months ending June 30, 2020, reporting revenue of £0.2 million, down from £0.4 million in H1 2019. The loss for the period remained at £4.8 million. The cash balance as of June 30, 2020, was £13.8 million, down from £18.8 million at the end of 2019. The company completed its De Novo FDA submission for the Parsortix system aimed at metastatic breast cancer, with an expected FDA clearance in Q2 2021. Post-period fundraising raised £19.6 million to support ongoing commercialization efforts.

ANGLE plc has successfully completed the FDA's administrative review for its Parsortix system, seeking clearance for use with metastatic breast cancer. The full Class II De Novo submission aims for FDA clearance potentially by Q2 CY21. This submission follows five years of development and extensive documentation. The FDA has 150 days to make a decision post-submission acceptance. ANGLE's technology has the potential to be the first of its kind to capture intact circulating tumor cells from blood for analysis, marking a significant advancement in non-invasive cancer diagnostics.

ANGLE plc (OTCQX: ANPCY) announced the grant of up to 3,000,000 Long-Term Incentive Plan (LTIP) options to executive directors and up to 4,940,000 share options to staff, contingent on performance conditions. The Remuneration Committee highlighted that these awards follow a suspension of the Annual Bonus Plan amid the COVID-19 pandemic. The LTIP aims to enhance shareholder value, with performance tied to FDA clearance for the Parsortix system and share price growth. Post-grant, total options outstanding will reach approximately 26,810,806, representing 13.0% of the issued share capital.

ANGLE plc has submitted a full Class II De Novo FDA Submission for its Parsortix system, aiming for clearance to harvest intact cancer cells from blood specifically for metastatic breast cancer patients. The Submission includes data from over 15,000 clinical samples, demonstrating the system's effectiveness in providing non-invasive, repeatable liquid biopsies. With an estimated market potential of US$2.4 billion annually for MBC, successful FDA clearance could significantly enhance ANGLE's competitive positioning in the liquid biopsy market.

ANGLE plc announced notable research from the University of Basel using its Parsortix system, highlighting how intra-tumour hypoxia influences metastatic breast cancer. Circulating tumour cell (CTC) clusters, found to be significantly more likely to cause metastasis, underscore the need for further exploration of their role in cancer spread. The study suggests that therapies targeting vascularisation, like EphrinB2, could mitigate metastasis by reducing hypoxia. This research supports the Parsortix system's potential in cancer drug discovery, particularly for FDA submissions.

ANGLE plc (OTCQX:ANPCY) announced a change in major shareholder holdings. On September 7, 2020, Legal & General Group Plc crossed below a 3% threshold, down from a previous holding of 6.98%. This reduction signifies a shift in voting rights, as the number of voting rights attached to shares now reflects below 3% of the total 172,796,483 voting rights in issue. The notification highlights the continued management of shares by Legal & General, despite the reduction in direct ownership. This change is crucial for current and prospective investors tracking shareholder dynamics.

On September 8, 2020, ANGLE plc (OTCQX:ANPCY) reported a major holdings notification, revealing that FIL Limited has crossed a voting rights threshold, now holding 5.76% of voting rights. This is a notable increase from a prior holding of 5.03%. The report confirms that FIL Limited, based in Pembroke, Bermuda, acquired these rights on September 7, 2020, reflecting a change in their controlled undertaking structure. The total number of voting rights stands at 172,796,483.

ANGLE plc (OTCQX:ANPCY) has announced it will release its interim results for the six months ended 30 June 2020 on 29 October 2020. This extension aligns with COVID-19 regulations set by AIM. A virtual meeting for analysts will be held at 10:00 am on the same day, with details to follow. ANGLE's liquid biopsy technology includes the Parsortix® system, which enables effective cancer cell isolation for analysis. The company is progressing towards FDA clearance for its CTC harvesting system, aiming to revolutionize cancer diagnostics with significant accuracy demonstrated in clinical studies.

ANGLE plc has received a notification of major holdings from Jupiter Fund Management Plc, indicating that their voting rights have decreased from 10.92% to 9.96% as of August 28, 2020. The notice, submitted on September 1, 2020, shows that Jupiter currently holds 17,218,184 voting rights out of a total of 172,796,483 for the issuer. This change reflects a shift in the ownership structure impacting voting rights in the company.